Response Evaluation Criteria In Solid Tumours (RECIST) remain an integral part of the assessment of tumour burden in many clinical trials in oncology; these criteria are used to evaluate the activity ...

We examined the impact of the number of target lesions (TLs) on within-patient variability of tumor response. The prognostic effect of TL response (at 12 weeks or on study on the basis of a maximum ...

Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New ...

Oncologists and researchers use a measurement known as Response Evaluation Criteria in Solid Tumors (RECIST) to evaluate the degree to which a patient's cancer responds to treatment during clinical ...

Most oncology trials, including TIGER-X, use a standard method to assess tumor response called the Response Evaluation Criteria in Solid Tumors (RECIST). 3 Under RECIST, a partial response must be ...

Outcomes among patients with stage IV non–small cell lung cancer as evaluated within clinical trials via Response Evaluation Criteria in Solid Tumors (RECIST) and clinician response criteria in ...

The first, formal revision of specific guidelines, known as RECIST, used by clinicians to measure tumor size and response to treatment, has just been published. The authors say that the revisions will ...

Researchers from the University of Colorado Cancer Center on the Anschutz Medical Campus have created a new way of measuring cancer lesions response to treatment that could better inform the ...

New insights into Response Evaluation Criteria in Solid Tumors (RECIST) criteria can help us compare the effectiveness of different treatments across different research trials more effectively found a ...

Oncologists and researchers use a measurement known as Response Evaluation Criteria in Solid Tumors (RECIST) to evaluate the degree to which a patient's cancer responds to treatment during clinical ...